{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T18:17:50Z","timestamp":1774462670481,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,7,24]],"date-time":"2014-07-24T00:00:00Z","timestamp":1406160000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","europeanneuropsychopharmacology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.euroneuro.2014.07.009","type":"journal-article","created":{"date-parts":[[2014,7,27]],"date-time":"2014-07-27T09:31:43Z","timestamp":1406453503000},"page":"1698-1708","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["ASP5736, a novel 5-HT5A receptor antagonist, ameliorates positive symptoms and cognitive impairment in animal models of schizophrenia"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1654-1851","authenticated-orcid":false,"given":"Mayako","family":"Yamazaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0449-7574","authenticated-orcid":false,"given":"Katsuya","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyuki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junko","family":"Yarimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayuko","family":"Okabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keni","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuya","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2014.07.009_bib1","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/sj.npp.1300394","article-title":"Spatial memory deficits induced by perinatal treatment of rats with PCP and reversal effect of d","volume":"29","author":"Andersen","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2014.07.009_bib2","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1038\/sj.npp.1300772","article-title":"Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic","volume":"30","author":"Depoortere","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2014.07.009_bib3","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S0006-8993(00)02383-0","article-title":"Localization of serotonin5A rexeptors in discrete regions of the circadian timing system in the Syrian hamster","volume":"869","author":"Duncan","year":"2000","journal-title":"Brain Res."},{"key":"10.1016\/j.euroneuro.2014.07.009_bib4","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0166-4328(88)90157-X","article-title":"A new one trial test for neurological studies of memory in rats. 1: behavioral data","volume":"31","author":"Ennaceur","year":"1988","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.euroneuro.2014.07.009_bib5","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1073\/pnas.90.8.3452","article-title":"Two members of a distinct subfamily of 5-hydroxytryptamine receptors differentially expressed in rat brain","volume":"90","author":"Erlander","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.euroneuro.2014.07.009_bib6","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0014-2999(98)00744-4","article-title":"The human 5-ht5A receptor couples to Gi\/G0 proteins and inhibits adenylate cyclase in HEK 293 cells","volume":"361","author":"Francken","year":"1998","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2014.07.009_bib7","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0014-2999(01)00933-5","article-title":"Human 5-HT5 receptors: the 5-HT5A receptor is functional but the 5-HT5B receptor was lost during mamalian evolution","volume":"418","author":"Grailhe","year":"2001","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2014.07.009_bib8","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1176\/ajp.153.3.321","article-title":"What are the functional consequences of neurocognitive deficits in schizophrenia?","volume":"153","author":"Green","year":"1996","journal-title":"Am. J. Psychiatry"},{"issue":"Suppl. 9","key":"10.1016\/j.euroneuro.2014.07.009_bib10","first-page":"S3","article-title":"Cognitive impairment and functional outcome in schizophrenia and bipolar disorder","volume":"67","author":"Green","year":"2006","journal-title":"J Clin Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.euroneuro.2014.07.009_bib11","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejphar.2012.04.013","article-title":"A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer\u05f3s disease","volume":"685","author":"Harada","year":"2012","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2014.07.009_bib12","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/sj.bjp.0703357","article-title":"Characterization of SB-269970-A, a selective 5-HT7 receptor antagonist","volume":"130","author":"Hagan","year":"2000","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.euroneuro.2014.07.009_bib13","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1586\/ern.09.143","article-title":"Effect of second-generation antipsychotics on cognition: current issues and future challenges","volume":"10","author":"Hill","year":"2010","journal-title":"Expert Rev. Neurother."},{"issue":"5\u20136","key":"10.1016\/j.euroneuro.2014.07.009_bib14","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.eurpsy.2005.02.006","article-title":"Patient outcomes in schizophrenia II: the impact of cognition.","volume":"20","author":"Hofer","year":"2005","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.07.009_bib15","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1038\/sj.bjp.0701928","article-title":"Functional coupling of a recombinant human 5-HT5A receptor to G-proteins in HEK-293 cells","volume":"124","author":"Hurley","year":"1998","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2014.07.009_bib16","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1176\/ajp.148.10.1301","article-title":"Recent advances in the phencyclidine model of schizophrenia","volume":"148","author":"Javitt","year":"1991","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2014.07.009_bib17","unstructured":"Jongen-Relo, A.L., Bespalov, A.Y., Rueter, L.E., Freeman, A.S., Decker, M.W., Gross, G., Schoemaker, H., Sullivan, J.P., vanGaleen, M.M., Wicke, K.M., Zhang, M., Amberg, W. and Garcia-Ladona, F.J., 2006. Behavioral pharmacological characterization of 5-HT5A receptor antagonists in antipsychologic drug tests. In: Proceedings of the 36th Annual Meeting of Society of Neuroscience, Atlanta, USA, October 14\u201318, Abstract 529.26."},{"key":"10.1016\/j.euroneuro.2014.07.009_bib18","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0169-328X(01)00034-1","article-title":"Distribution of 5-HT5A, 5-HT5B, 5-HT6 an 5-HT7 receptor mRNAs in the rat brain","volume":"88","author":"Kinsey","year":"2001","journal-title":"Mol. Brain Res."},{"key":"10.1016\/j.euroneuro.2014.07.009_bib19","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.brainres.2009.05.004","article-title":"Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent subchronic administration of donepezil: role of sigma-1 receptors","volume":"1279","author":"Kunitachi","year":"2009","journal-title":"Brain Res."},{"key":"10.1016\/j.euroneuro.2014.07.009_bib20","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0026-895X(25)13615-8","article-title":"Mouse 5-hydroxytryptamine5A and 5-hydroxytryptamine5B receptors define a new family of serotonin receptors: cloning, functional expression, and chromosomal localization","volume":"43","author":"Matthes","year":"1993","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.euroneuro.2014.07.009_bib21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0014-2999(97)83020-8","article-title":"SA4503, a novel cognitive enhancer with [sigma]1 receptor agonist properties, facilitates NMDA receptor-dependent learning in mice","volume":"328","author":"Maurice","year":"1997","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.euroneuro.2014.07.009_bib22","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1101\/lm.89805","article-title":"Working memory deficits in retinoid X receptor r-deficient mice","volume":"12","author":"Marta","year":"2005","journal-title":"Learn. Mem."},{"key":"10.1016\/j.euroneuro.2014.07.009_bib23","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1046\/j.1471-4159.2003.01518.x","article-title":"Recombinant human serotonin5A receptors stably expressed in C6 glioma cells couple to multiple signal transduction pathways","volume":"84","author":"Noda","year":"2003","journal-title":"J. Neurochem."},{"issue":"4","key":"10.1016\/j.euroneuro.2014.07.009_bib24","first-page":"2278","article-title":"Elevated plus maze and T-maze behavioral effects of subchronic, oral low dose monosodium glutamate in swiss albino mice","volume":"3","author":"Olakunle","year":"2012","journal-title":"J. Pharmacy Biol. Sci."},{"key":"10.1016\/j.euroneuro.2014.07.009_bib25","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0006-8993(00)02273-3","article-title":"Localization of 5-HT5A receptor-like immunoreactivity in the rat brain","volume":"867","author":"Oliver","year":"2000","journal-title":"Brain Res."},{"key":"10.1016\/j.euroneuro.2014.07.009_bib26","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/0028-3908(90)90034-O","article-title":"Excitatory amino acid antagonists and memory: effect of drugs acting at N-methyl-d-aspartate receptors in learning and memory tasks","volume":"29","author":"Parada-Turska","year":"1990","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2014.07.009_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0169-328X(98)00003-5","article-title":"Distribution of the 5-HT5A serotonin receptor mRNA in the human brain","volume":"56","author":"Pasqualetti","year":"1998","journal-title":"Mol. Brain Res."},{"issue":"3","key":"10.1016\/j.euroneuro.2014.07.009_bib28","doi-asserted-by":"crossref","first-page":"pp342","DOI":"10.1021\/jm991151j","article-title":"A novel, potent, and selective 5-HT7 antagonist:(R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl)phenol (SB-269970)","volume":"43","author":"Peter","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.euroneuro.2014.07.009_bib29","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.1002\/j.1460-2075.1992.tb05583.x","article-title":"The mouse 5HT5 receptor reveals a remarkable heterogeneity within the 5HT1D receptor family","volume":"11","author":"Plassat","year":"1992","journal-title":"EMBO J."},{"key":"10.1016\/j.euroneuro.2014.07.009_bib30","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/0014-5793(94)01209-1","article-title":"Cloning and characterisation of the human 5-HT5A serotonin receptor","volume":"355","author":"Rees","year":"1994","journal-title":"FEBS Lett."},{"key":"10.1016\/j.euroneuro.2014.07.009_bib31","unstructured":"Rueter, L.E., Wicke, K.M., Basso, A.M., Jongen-Relo, A.L., van Galeen, M.M., Gross, G., Decker, M.W., Kling, A., Schoemarker, H., Sullivan, J.P., Amberg, W. and Garcia-Ladona, F.J., 2006. Characterization of 5-HT5A antagonists in models of depression and anxiety. In: Proceedings of the 36th Annual Meeting of Society of Neuroscience, Atlanta. USA, October 14\u201318, Abstract 33.3."},{"key":"10.1016\/j.euroneuro.2014.07.009_bib32","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.pharmthera.2005.12.006","article-title":"5-ht5A receptors as a therapeutic target","volume":"111","author":"Thomas","year":"2006","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.euroneuro.2014.07.009_bib33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0304-3940(99)00905-2","article-title":"5-HT5A receptors in the carotid body chemoreception pathway of rat","volume":"278","author":"Wang","year":"2000","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.euroneuro.2014.07.009_bib34","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0306-4522(01)00384-0","article-title":"Long-term behavioral and neurodegenerative effects of perinatal phencyclidine administration: implications for schizophrenia","volume":"107","author":"Wang","year":"2001","journal-title":"Neuroscience"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X14002065?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X14002065?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T23:27:33Z","timestamp":1746314853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X14002065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0924977X14002065"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2014.07.009","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ASP5736, a novel 5-HT5A receptor antagonist, ameliorates positive symptoms and cognitive impairment in animal models of schizophrenia","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2014.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. and ECNP.","name":"copyright","label":"Copyright"}]}}